Literature DB >> 32303781

Inhibition of glycolysis ameliorate arthritis in adjuvant arthritis rats by inhibiting synoviocyte activation through AMPK/NF-кB pathway.

Ying Wang1,2, Hao Xian2, Jiajia Qi2, Fang Wei1,2, Xiu Cheng2, Sha Li2, Qing Wang1,2, Zhaoyang Liu2, Yun Yu2, Jing Zhou2, Xiaojin Sun1,2, Hao Liu1,2, Yingmei Wei3,4.   

Abstract

OBJECTIVE: This study aimed to evaluate glycolysis inhibitor which can effectively ameliorate arthritis by inhibiting synoviocyte activation through AMPK/NF-кB pathway in AA rats.
METHODS: Adjuvant arthritis (AA) rats were treated with 2-deoxyglucose (2-DG), glycolysis inhibitor. HE staining and radiological Examination were used for histopathology analysis and evaluation of joint destruction. HKII expression was quantified by immunostaining. Proliferation and migration of synoviocytes were assessed by synovicyte scores of joint, CCK8 and transwell assay. Inflammatory factors and levels of AMPK, p65 and IκBα were quantified by ELISA analysis and WB.
RESULTS: We observed that HKII expression was positively correlated with synovial hyperplasia, inflammatory cell infiltration, and cartilage destruction, and glycolysis inhibitor reduces the joint swelling degree, alleviates bone destruction, inhibits the proliferation and migration of synoviocyte, and reduces secretory function of synoviocytes in AA rats. In addition, we investigated that glycolysis inhibitor may inhibit activation of the NF-κB signaling pathway by activating the AMPK pathway.
CONCLUSION: This study suggests the involvement of energy metabolism in the pathological inflammation process in RA joints. Glycolysis inhibitors might, therefore, provide an opportunity for therapeutic intervention.

Entities:  

Keywords:  AMP-activated protein kinase; Glycolytic metabolites; Nuclear factor-κB; Rheumatoid arthritis; Synoviocyte

Mesh:

Substances:

Year:  2020        PMID: 32303781     DOI: 10.1007/s00011-020-01332-2

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  7 in total

Review 1.  AMPK: implications in osteoarthritis and therapeutic targets.

Authors:  Junjie Wang; Jiali Li; Deye Song; Jiangdong Ni; Muliang Ding; Jun Huang; Mingming Yan
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

Review 2.  Glycolysis in Innate Immune Cells Contributes to Autoimmunity.

Authors:  Yue Xu; Yongkang Chen; Xuan Zhang; Jie Ma; Yudong Liu; Liyan Cui; Fang Wang
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 3.  Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism.

Authors:  Rafael Agustín Burgos; Pablo Alarcón; John Quiroga; Carolina Manosalva; Juan Hancke
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

Review 4.  Glycolysis Rate-Limiting Enzymes: Novel Potential Regulators of Rheumatoid Arthritis Pathogenesis.

Authors:  Jianlin Zuo; Jinshuo Tang; Meng Lu; Zhongsheng Zhou; Yang Li; Hao Tian; Enbo Liu; Baoying Gao; Te Liu; Pu Shao
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

5.  Transdermal delivery of triptolide-phospholipid complex to treat rheumatoid arthritis.

Authors:  Xin-Yi Liu; Wen-Jun Pei; Ye-Zhen Wu; Fang-Li Ren; Si-Yu Yang; Xiu Wang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 6.  HK2: a potential regulator of osteoarthritis via glycolytic and non-glycolytic pathways.

Authors:  Chuncha Bao; Siyi Zhu; Kangping Song; Chengqi He
Journal:  Cell Commun Signal       Date:  2022-08-30       Impact factor: 7.525

Review 7.  Rheumatoid arthritis and mitochondrial homeostasis: The crossroads of metabolism and immunity.

Authors:  Liu Cui; Jing Weiyao; Su Chenghong; Liu Limei; Zhang Xinghua; Yuan Bo; Du Xiaozheng; Wang Haidong
Journal:  Front Med (Lausanne)       Date:  2022-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.